Benefits
IBS-D and post-infectious IBS — strongest gut evidence
In post-infectious diarrhea-predominant IBS, 15 g/day (5 g three times daily) over 8 weeks produced a striking effect: 79.6% of the glutamine group achieved a >50-point IBS-SSS (symptom severity score) reduction vs 5.8% with placebo. The effect size is much larger than typical IBS interventions. Most relevant for IBS-D specifically (especially post-infectious onset), not all IBS subtypes. Mechanism: glutamine fuels enterocyte renewal and tight-junction protein synthesis.
Intestinal permeability — dose-dependent
Overall analysis shows NO significant effect at typical supplemental doses on gut permeability markers. Subgroup analysis: significant reduction emerges only with doses >30 g/day for durations under 2 weeks. Major implication: standard 5-10 g/day 'leaky gut' protocols are below the effective dose threshold for permeability outcomes. The exception is exercise-induced permeability. In ten recreationally active men, single doses of 0.25, 0.5 and 0.9 g per kg of fat-free mass taken two hours before a hot 60-minute run lowered a dual-sugar marker of gut leakiness versus placebo, with the biggest effect at the highest dose. Note the basis is fat-free mass, so even the low dose is roughly 14 g for a typical adult and the high dose is around 50 g. It is one small acute study in ten people, and gut symptoms themselves did not improve.
Sickle cell disease — FDA-approved indication
L-glutamine (branded as Endari®) is FDA-approved for sickle cell disease in patients ≥5 years old. At 0.3 g/kg twice daily over 48 weeks, it reduced sickle cell crises by 25% (3.0 vs 4.0 events/year), hospitalizations by 33% (2.0 vs 3.0), and shortened hospitalization duration vs placebo. Mechanism: glutamine supports NAD+/NADH redox balance in red blood cells, reducing oxidative damage and sickling triggers. Read this as a fact about a prescription medicine, not as a reason to buy a supplement. Endari is pharmaceutical-grade L-glutamine prescribed and monitored by a hematologist, the pivotal trial was funded by the manufacturer and has not been independently repeated, and about two thirds of patients in both groups were also on hydroxyurea. A tub of supplement-grade glutamine powder is not a substitute for it. Sickle cell disease is serious and nobody should self-treat it, stop or change a prescribed treatment, or copy the trial dose without their specialist.
Critical illness — caution required
A trial in 1,223 mechanically ventilated critically ill adults across 40 intensive care units found higher 28-day mortality with high-dose glutamine (32.4% versus 27.2%), and in-hospital and 6-month mortality were significantly higher. The antioxidant arm of the same trial had no effect on mortality, so the signal belongs to glutamine itself, not to the antioxidants. This reset prior enthusiasm for routine glutamine in ICU patients. European and American guidelines now caution against glutamine in shock and multi-organ failure. Burns were long treated as the surviving exception, but a separate trial in 1,209 patients with severe burns, who received glutamine through a feeding tube or by mouth, found no shortening of time to discharge alive and no improvement in survival, so that exception is now much weaker. Short bowel syndrome remains a specialist decision made by a treating team, not a self-care one.
Athletic recovery — overrated in marketing
Despite heavy marketing for muscle recovery, the trial evidence is weak. A meta-analysis that pooled 25 trials in physically active adults concluded that glutamine has no effect on aerobic performance, body composition or immune measures, and a six-week resistance training trial in 31 young adults found no extra gain in strength, torque or lean mass over placebo even at about 0.9 g per kilogram of lean tissue mass a day, far above a normal supplement serving. One small crossover in 16 people did report less soreness and faster strength recovery after eccentric exercise at about 0.3 g per kilogram per day, but a single crossover that size cannot carry the claim on its own. Glutamine stores in muscle are typically maintained adequately by dietary protein in well-fed athletes. The more plausible benefit is protection against exercise-induced gut permeability — particularly relevant for endurance athletes prone to GI distress during training.
Chemotherapy mucositis and short bowel syndrome
Used in oncology supportive care, with results that do not all point the same way. A meta-analysis of 15 randomized trials in 988 cancer patients found glutamine did not reduce how often mouth sores occurred but did reduce their severity and the number of severe cases, along with opioid use, feeding tube use and hospitalization. A separate meta-analysis of 6 trials in 441 patients with head and neck cancer found no clinical benefit from oral glutamine for radiation-induced mouth sores. Mouth-sore trials also often deliver glutamine as a rinse or a swish-and-swallow suspension aimed at the mouth lining, which is not the same exposure as swallowing a supplement drink. Glutamine also appears in specialized rehydration solutions used in short bowel syndrome, where it acts both as a sodium cotransport substrate and as fuel for the gut lining. That is a hospital application managed by a treating team, not a consumer one. Tumor-cell-uptake concerns (theoretical 'feeding cancer') are generally not supported by clinical data.
Wound healing and surgical recovery
Earlier and mostly small trials in burn and surgical patients reported faster wound healing and fewer infections, and a systematic review of 53 trials in 4,671 critically ill or major surgery patients did find fewer infectious complications with glutamine, though no reduction in deaths. That picture has since been undercut where it was strongest: a trial in 1,209 patients with severe burns found that glutamine by feeding tube did not shorten time to discharge alive and did not improve six-month survival. Almost all of this evidence comes from hospital nutrition support delivered by feeding tube or intravenously in seriously ill patients, which is not the same as swallowing supplement powder, and none of it validates glutamine for wound healing or skin appearance in otherwise healthy adults.
Sodium cotransport and oral rehydration
Glutamine functions as a sodium cotransport substrate in the small intestine, supporting fluid absorption parallel to glucose-mediated SGLT1. The absorption mechanism is real, but the hydration outcome is not. In rats given cholera toxin, both a free glutamine solution and an alanyl-glutamine dipeptide solution reduced sodium and water secretion, and in six healthy adults glutamine perfused directly into the jejunum through a tube roughly tripled water and sodium absorption. Where glutamine has been tested as something a person actually drinks, though, it has not delivered. A double-blind trial in 147 dehydrated children found a glutamine-based, glucose-free rehydration solution was no better than standard WHO oral rehydration solution for stool output, time to rehydrate, or the volume of solution needed. A hydration study in 19 healthy adults found a drink containing an alanyl-glutamine dipeptide held fluid better than plain water but no better than the same drink with electrolytes alone, and the authors concluded the electrolytes did most of the work. Glutamine-containing rehydration solutions do have a narrow specialist role in short bowel syndrome, which is a decision made by a treating team. On the evidence to date glutamine is not a hydration aid in its own right, which is why hydration is not listed as a use for it here.
Mechanism of action
Primary fuel for enterocytes
Glutamine supplies 60-70% of energy for small intestinal epithelial cells (enterocytes), which turn over every 3-5 days. It's the single most important nutrient for maintaining intestinal barrier integrity. Enterocytes preferentially metabolize glutamine over glucose. This is the molecular basis for the gut-related clinical applications.
Conditionally essential under stress
Endogenous glutamine synthesis (primarily skeletal muscle) typically meets demand. During catabolic stress — sepsis, burns, major surgery, prolonged intense exercise — demand exceeds production, depleting muscle and plasma glutamine pools. Supplementation rationale strongest in these stress states; less clear in healthy adults at rest.
Immune cell substrate
Lymphocytes, macrophages, and neutrophils require glutamine at rates similar to glucose. Glutamine availability affects T-cell proliferation, cytokine production, and phagocytic function. This is the rationale behind trials of glutamine for preventing infection after surgery, and it remains a rationale rather than a demonstrated consumer benefit. The largest intensive care trial of high-dose glutamine found higher mortality, and in healthy, well-fed people glutamine supplementation has not improved immune measures.
Nitrogen carrier and acid-base balance
Glutamine is the major non-toxic transport form for nitrogen between tissues. Renal glutamine catabolism produces ammonia for excretion, contributing to acid-base homeostasis. Plays key role in interorgan amino acid metabolism.
Sickle cell redox protection
Glutamine supports NAD+/NADH balance in red blood cells, reducing oxidative damage that triggers sickling. Mechanism behind FDA-approved Endari® indication. Sickle cells have reduced glutamine uptake capacity, making supraphysiologic doses necessary for therapeutic effect.
Clinical trials
Double-blind randomized placebo-controlled trial of oral L-glutamine for post-infectious diarrhea-predominant IBS. Outcomes measured via the IBS Symptom Severity Score (IBS-SSS) — a validated, well-established instrument with a >50-point reduction threshold for clinically meaningful improvement. Published in the journal Gut.
106 patients with post-infectious diarrhea-predominant IBS. 8-week intervention.
L-glutamine 5 g three times daily (15 g/day total) over 8 weeks produced a 79.6% responder rate (>50-point IBS-SSS reduction) vs only 5.8% with placebo — a striking effect size compared to most IBS interventions. The trial established post-infectious IBS-D as the strongest indication for glutamine in gut disorders and supported the biological plausibility that supplementation supports enterocyte renewal.
Evidence review and pooled analysis of clinical trials evaluating L-glutamine supplementation for intestinal permeability outcomes (the 'leaky gut' framework). Included trials assessed permeability via lactulose-mannitol ratio or related markers. Published in Amino Acids. Subgroup analyses by dose, duration, and population.
Multiple trials across various adult populations. Doses ranging from typical supplemental (5-10 g/day) to high-dose clinical use (>30 g/day).
Overall analysis showed NO significant effect on permeability at typical supplemental doses (WMD -0.00, 95% CI -0.04 to 0.03). Subgroup analysis identified a significant effect only at doses >30 g/day for short durations (<2 weeks). Major practical implication: standard 5-10 g/day 'leaky gut' protocols are below the effective dose threshold demonstrated for permeability outcomes.
Phase 3 randomized double-blind placebo-controlled trial supporting FDA approval of L-glutamine (Endari®, Emmaus Medical) for sickle cell disease in 2017. Primary outcome: number of pain crises. Secondary outcomes: hospitalizations, acute chest syndrome, hospital length of stay. Published in NEJM.
230 patients ≥5 years old with sickle cell anemia or sickle β⁰-thalassemia. 48-week intervention.
L-glutamine 0.3 g/kg twice daily reduced median sickle cell crises by 25% (3.0 vs 4.0 events/year), hospitalizations by 33% (2.0 vs 3.0), and shortened hospitalization duration vs placebo. Effects emerged across the 48-week protocol. Foundation for the 2017 FDA approval and current use as a daily prescription therapy in sickle cell disease. Three limits belong alongside that: the trial was funded by the manufacturer, Emmaus Medical, and has not been independently repeated; roughly two thirds of patients in both groups were also taking hydroxyurea, so the effect is an add-on to standard care; and nausea, noncardiac chest pain, fatigue and musculoskeletal pain were more common on glutamine. This is a prescription medicine used under specialist supervision, not a supplement regimen to copy.
Large multicenter randomized controlled trial evaluating high-dose glutamine and antioxidants in mechanically ventilated critically ill patients. 2×2 factorial design with parenteral and enteral glutamine supplementation. Primary outcome: 28-day mortality. Published in NEJM. Conducted across multiple ICUs in North America and Europe.
1,223 mechanically ventilated critically ill adults across multiple ICUs. ICU-stay-duration intervention.
In the glutamine comparison, 28-day mortality was higher with glutamine (32.4% versus 27.2%, p=0.05), and in-hospital and 6-month mortality were significantly higher. The antioxidant factor had no effect on mortality (30.8% versus 28.8%, p=0.48), so the harm signal attaches to glutamine itself rather than to the antioxidants. This finding reset prior enthusiasm for routine glutamine in critical care. Guidelines in Europe and North America now caution against glutamine in shock and multi-organ failure. The burns exception has since weakened as well: a separate trial in 1,209 patients with severe burns, who received glutamine through a feeding tube or by mouth, found no shortening of hospital stay and no improvement in survival.
Dose-response study evaluating oral L-glutamine for prevention of exercise-induced intestinal permeability — a known issue in endurance athletes that contributes to GI distress and 'leaky gut' biomarkers during prolonged exercise. Permeability assessed via lactulose-rhamnose or related dual-sugar absorption methods.
Ten recreationally active men, each completing four trials in a crossover design: a placebo trial and three glutamine doses taken two hours before a 60-minute treadmill run at 30 degrees Celsius.
Doses of 0.25, 0.5 and 0.9 g per kg of fat-free mass all lowered the lactulose to rhamnose permeability ratio versus placebo, with the largest reduction at the highest dose. The dosing basis is fat-free mass, not body mass, so the low dose is roughly 14 g and the high dose roughly 50 g for a typical adult. Gut symptoms were low throughout and supplementation did not change them, and the results were reported as likelihoods rather than conventional significance tests in ten participants. Useful evidence that the very-high-dose threshold for permeability outcomes in the broader pooled analysis doesn't necessarily apply in the specific context of exercise-stress permeability — which may be more responsive to acute dosing strategies.